Product Information
ATAZANAVIR SULFATE 300 MG CAP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $2.2264 per EA under NDC 00093552856. Its NADAC has been published 416 times since Mar 21, 2018.
FDA first approved this application on Apr 22, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093552856
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATAZANAVIR SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA091673FDA Approved
4/22/2014
TE Code
AB
On Market Since
12/27/2017
Pharmacological Classes
Price Statistics
The NADAC for ATAZANAVIR SULFATE 300 MG CAP has been published 416 times since Mar 21, 2018, and over the history we have for it it has declined 91.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2264 per EA |
|---|---|
| All-time high | $29.0173 (May 16, 2018) |
| All-time low | $1.7959 (Aug 21, 2024) |
| 52-week high | $3.0949 |
| 52-week low | $2.2264 |
| Median price | $5.9101 |
| Average price | $6.7568 |
| Largest weekly change | -43.2% (Sep 19, 2018) |
| Weeks tracked | 416 |
| Tracking since | Mar 21, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Atazanavir Sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Atazanavir Sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Protease Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATAZANAVIR SULFATE 300 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for ATAZANAVIR SULFATE 300 MG CAP, manufactured by Teva Pharmaceuticals USA Inc., is $2.2264 per EA (NDC 00093552856), effective Sep 30, 2026.
How has the price of ATAZANAVIR SULFATE 300 MG CAP changed over time?
Over the history we have for it, the NADAC for ATAZANAVIR SULFATE 300 MG CAP has declined 91.6%. It has been tracked across 416 weekly CMS publications since Mar 21, 2018.
What are the highest and lowest recorded NADAC prices for ATAZANAVIR SULFATE 300 MG CAP?
Since Mar 21, 2018, the NADAC for ATAZANAVIR SULFATE 300 MG CAP has ranged from a low of $1.7959 (Aug 21, 2024) to a high of $29.0173 (May 16, 2018), with a median of $5.9101 per EA.
Are there cheaper alternatives to ATAZANAVIR SULFATE 300 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of ATAZANAVIR SULFATE 300 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ATAZANAVIR SULFATE 300 MG CAP?
ATAZANAVIR SULFATE 300 MG CAP (NDC 00093552856) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.